Active Biotech AB Interim Report January-June 2006

LUND, SWEDEN -- (MARKET WIRE) -- August 10, 2006 -- * Final report from Phase II study of laquinimod to be presented before year-end * ANYARA Phase II/III renal cancer study to start in Q4 * Recruitment for Phase I TASQ study completed; evaluation scheduled for Q3 * Preclinical data for 57-57 supports ongoing clinical development * Net sales: SEK 11.4 million (5.8) * Operating loss: SEK 79.3 million (loss: 100.5) * Loss after tax: SEK 83.4 million (loss: 110.3) * Loss per share for the period: SEK 2.10 (loss: 3.18)

Back to news